Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H2 2015

Published: Oct, 2015 | Pages: 133 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H2 2015', provides an overview of the Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents
 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Overview 9
Therapeutics Development 10
Pipeline Products for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Overview 10
Pipeline Products for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Comparative Analysis 11
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Therapeutics under Development by Companies 12
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Therapeutics under Investigation by Universities/Institutes 14
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Products under Development by Companies 18
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Products under Investigation by Universities/Institutes 20
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Companies Involved in Therapeutics Development 21
Altor BioScience Corporation 21
APIM Therapeutics AS 22
Astellas Pharma Inc. 23
Bavarian Nordic A/S 24
BioCancell Ltd 25
Celgene Corporation 26
Cold Genesys, Inc. 27
Heat Biologics, Inc. 28
Spectrum Pharmaceuticals, Inc. 29
TARIS BioMedical, Inc. 30
Telesta Therapeutics Inc. 31
Telormedix SA 32
Vakzine Projekt Management GmbH 33
Viralytics Ltd. 34
Viventia Biotechnologies Inc. 35
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Target 37
Assessment by Mechanism of Action 39
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
ALT-801 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
ALT-803 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
apaziquone - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
APL-1202 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
ATX-101 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
BC-819 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Biologic for Superficial Bladder Cancer - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
CG-0070 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
CV-301 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
CVA-21 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
DAB-389EGF - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
docetaxel - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Drug for NMIBC - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
erlotinib hydrochloride - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
imiquimod - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
lenalidomide - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
mitomycin SR - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Monoclonal Antibody to Inhibit EGFR for Superficial Bladder Cancer - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
oportuzumab monatox - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
rAd-IFN - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
sirolimus albumin-bound - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
TD-210 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Urocidin - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
vesigenurtucel-L - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
VPM-1002 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Recent Pipeline Updates 92
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Dormant Projects 123
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Discontinued Products 124
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Product Development Milestones 125
Featured News & Press Releases 125
Sep 28, 2015: Telesta Announces FDA Advisory Committee Date for MCNA 125
Aug 28, 2015: Telesta Receives FDA BLA Filing Notification Letter and Priority Review Designation for MCNA 125
Aug 17, 2015: Spectrum Pharmaceuticals Announces Agreement with FDA on the Special Protocol Assessment (SPA) for the Upcoming Apaziquone Phase 3 Trial in Patients with Non-Muscle Invasive Bladder Cancer 126
Jul 02, 2015: Viventia Begins Recruitment of Clinical Centers as it Prepares to Initiate Phase 3 Clinical Trial of Vicinium(TM) for the Treatment of Non-Muscle-Invasive Bladder Cancer 127
Jun 30, 2015: Telesta Therapeutics Submits Biologics License Application to the U.S. FDA 127
Jun 03, 2015: Telesta Therapeutics Announces Issuance of Key U.S. MCNA Composition of Matter Patent 128
Mar 09, 2015: Heat Biologics Receives US FDA Fast Track Designation for HS-410 (Vesigenurtacel L) in Combination With BCG for the Treatment of Non-Muscle Invasive Bladder Cancer 128
Feb 26, 2015: Heat Biologics Provides Update at Key Opinion Leader Event 129
Jan 26, 2015: Heat Biologics Presents Positive Immunological Data on HS-410 in Non-Muscle Invasive Bladder Cancer at the 7th Annual Phacilitate Immunotherapy Forum 2015 130
Dec 01, 2014: Telesta Therapeutics Announces Key Clinical & Corporate Updates 131
Appendix 132
Methodology 132
Coverage 132
Secondary Research 132
Primary Research 132
Expert Panel Validation 132
Contact Us 132
Disclaimer 133

List of Tables

Number of Products under Development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), H2 2015 10
Number of Products under Development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 13
Number of Products under Investigation by Universities/Institutes, H2 2015 14
Comparative Analysis by Late Stage Development, H2 2015 15
Comparative Analysis by Clinical Stage Development, H2 2015 16
Comparative Analysis by Early Stage Development, H2 2015 17
Products under Development by Companies, H2 2015 18
Products under Development by Companies, H2 2015 (Contd...1) 19
Products under Investigation by Universities/Institutes, H2 2015 20
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Altor BioScience Corporation, H2 2015 21
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by APIM Therapeutics AS, H2 2015 22
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Astellas Pharma Inc., H2 2015 23
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Bavarian Nordic A/S, H2 2015 24
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by BioCancell Ltd, H2 2015 25
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Celgene Corporation, H2 2015 26
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Cold Genesys, Inc., H2 2015 27
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Heat Biologics, Inc., H2 2015 28
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015 29
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by TARIS BioMedical, Inc., H2 2015 30
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Telesta Therapeutics Inc., H2 2015 31
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Telormedix SA, H2 2015 32
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Vakzine Projekt Management GmbH, H2 2015 33
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Viralytics Ltd., H2 2015 34
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Viventia Biotechnologies Inc., H2 2015 35
Assessment by Monotherapy Products, H2 2015 36
Number of Products by Stage and Target, H2 2015 38
Number of Products by Stage and Mechanism of Action, H2 2015 40
Number of Products by Stage and Route of Administration, H2 2015 42
Number of Products by Stage and Molecule Type, H2 2015 44
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics - Recent Pipeline Updates, H2 2015 92
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Dormant Projects, H2 2015 123
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Discontinued Products, H2 2015 124